https://www.reuters.com/article/us-health-coronavirus-vaccine-approval-e-idUSKBN25K2M0
AUGUST 25, 2020 / 8:14 AM / UPDATED 11 HOURS AGO
Exclusive: Fauci says rushing out a vaccine could jeopardize testing of others
Julie Steenhuysen, Carl O'Donnell
国立アレルギー・感染症研究所所長のファウチ氏、新コロナウイルスのワクチンを急ぎすぎて
安全性確認などの為の大規模テストを待たずに緊急使用するというのは悪いアイデアだ

NEW YORK (Reuters) - The top U.S. infectious diseases expert is warning that
distributing a COVID-19 vaccine under special emergency use guidelines before it has
been proved safe and effective in large trials is a bad idea that could have a
chilling effect on the testing of other vaccines.

Scientists and health experts have expressed concern that President Donald Trump will
apply pressure on the U.S. Food and Drug Administration to deliver a vaccine before
November to boost his chances of re-election.

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases,
declined to comment on the president, but said there are risks in rushing out a
vaccine despite the urgent need.
“The one thing that you would not want to see with a vaccine is getting an EUA
(emergency use authorization) before you have a signal of efficacy,” Fauci told
Reuters in a phone interview.
“One of the potential dangers if you prematurely let a vaccine out is that it would
make it difficult, if not impossible, for the other vaccines to enroll people in their
trial,” Fauci said.

Large-scale clinical trials of the leading vaccine candidates from Moderna Inc (MRNA.O),
Pfizer Inc (PFE.N) andAstraZeneca Plc (AZN.L), which aim to enroll tens of thousands
of volunteers, were launched in recent weeks. Johnson & Johnson (JNJ.N) last week said
it hopes to include 60,000 subjects in its Phase III vaccine trial.